Free Trial

Lakewood-Amedex Biotherapeutics (LABT) Competitors

Lakewood-Amedex Biotherapeutics logo
$0.28 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.28 0.00 (-0.85%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LABT vs. ABP, CRIS, GOVX, PPBT, and PPCB

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? Lakewood-Amedex Biotherapeutics's main competitors and comparable companies include Abpro (ABP), Curis (CRIS), GeoVax Labs (GOVX), Purple Biotech (PPBT), and Propanc Biopharma (PPCB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakewood-Amedex Biotherapeutics compare to Abpro?

Abpro (NASDAQ:ABP) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Company Net Margins Return on Equity Return on Assets
AbproN/A N/A -344.76%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

23.3% of Abpro shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abpro
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Abpro is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbproN/AN/A-$7.23M-$4.23N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 3 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Abpro. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.50 beat Abpro's score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Abpro Neutral
Lakewood-Amedex Biotherapeutics Neutral

Summary

Lakewood-Amedex Biotherapeutics beats Abpro on 7 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Curis?

Curis (NASDAQ:CRIS) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Curis. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$9.44M0.19-$7.58M-$14.22N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A

In the previous week, Curis had 4 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 7 mentions for Curis and 3 mentions for Lakewood-Amedex Biotherapeutics. Curis' average media sentiment score of 0.81 beat Lakewood-Amedex Biotherapeutics' score of 0.50 indicating that Curis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Curis
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lakewood-Amedex Biotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

30.0% of Curis shares are owned by institutional investors. 1.5% of Curis shares are owned by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Curis' return on equity.

Company Net Margins Return on Equity Return on Assets
CurisN/A -639.43% -213.05%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

Curis currently has a consensus target price of $43.00, suggesting a potential upside of 9,562.92%. Given Curis' higher probable upside, equities research analysts clearly believe Curis is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Lakewood-Amedex Biotherapeutics beats Curis on 6 of the 11 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to GeoVax Labs?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

6.1% of GeoVax Labs shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 0.2% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GeoVax Labs has a consensus price target of $3,600.00, suggesting a potential upside of 210,426.32%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, GeoVax Labs had 4 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 7 mentions for GeoVax Labs and 3 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.50 beat GeoVax Labs' score of 0.40 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakewood-Amedex Biotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
GeoVax Labs$2.49M0.35-$21.47M-$11.34N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
GeoVax Labs N/A -1,010.68%-420.06%

Summary

Lakewood-Amedex Biotherapeutics beats GeoVax Labs on 7 of the 11 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Purple Biotech?

Purple Biotech (NASDAQ:PPBT) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Purple Biotech is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple BiotechN/AN/A-$26.39M-$23.25N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A

9.6% of Purple Biotech shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lakewood-Amedex Biotherapeutics had 2 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 1.82 beat Lakewood-Amedex Biotherapeutics' score of 0.50 indicating that Purple Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Purple Biotech Very Positive
Lakewood-Amedex Biotherapeutics Neutral

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Purple BiotechN/A -147.77% -111.59%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

Purple Biotech currently has a consensus target price of $30.00, indicating a potential upside of 1,864.64%. Given Purple Biotech's higher probable upside, equities research analysts clearly believe Purple Biotech is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Purple Biotech
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Lakewood-Amedex Biotherapeutics beats Purple Biotech on 7 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Propanc Biopharma?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Propanc Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
Propanc BiopharmaN/AN/A-$18.86M-$242.50N/A

In the previous week, Lakewood-Amedex Biotherapeutics and Lakewood-Amedex Biotherapeutics both had 3 articles in the media. Propanc Biopharma's average media sentiment score of 1.39 beat Lakewood-Amedex Biotherapeutics' score of 0.50 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Propanc Biopharma Positive

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Propanc Biopharma N/A -228.55%-160.66%

Summary

Lakewood-Amedex Biotherapeutics beats Propanc Biopharma on 6 of the 8 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABT vs. The Competition

MetricLakewood-Amedex BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$669K$4.13B$7.89B$12.08B
Dividend YieldN/A3.64%2.47%4.53%
P/E Ratio-0.0624.6434.5930.65
Price / SalesN/A16.368.645.80
Price / CashN/A21.8921.0222.32
Price / BookN/A4.504.803.95
Net Income-$3.85M-$24.19M$3.52B$391.64M
7 Day Performance-32.44%-4.44%-3.20%-2.48%
1 Month Performance-51.31%-2.06%-1.47%-3.98%
1 Year PerformanceN/A-1.72%1.46%-5.71%

Lakewood-Amedex Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABT
Lakewood-Amedex Biotherapeutics
0.5082 of 5 stars
$0.28
flat
N/AN/A$669KN/AN/A5
ABP
Abpro
N/A$0.52
flat
N/AN/A$1.42MN/AN/A15
CRIS
Curis
2.5598 of 5 stars
$0.91
+6.6%
$43.00
+4,643.5%
-98.3%$1.38M$9.44MN/A24
GOVX
GeoVax Labs
3.1238 of 5 stars
$0.16
+1.3%
$150.00
+93,650.0%
-99.4%$1.20M$2.49MN/A19
PPBT
Purple Biotech
2.5576 of 5 stars
$1.31
+4.8%
$30.00
+2,190.1%
-78.7%$1.14MN/AN/A10

Related Companies and Tools


This page (NASDAQ:LABT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners